Cantrixil has shown broad cytotoxic activity against chemoresistant ovarian cancer stem cell (CD44+ MyD88+) populations in both 2D and 3D in vitro models, as well as potent cytotoxic activity against non-stem like ovarian cancer cells. Here, CD44 is linked to ovarian carcinoma.